These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. He J; Hu Y; Hu M; Li B Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307 [TBL] [Abstract][Full Text] [Related]
13. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Langer CJ Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885 [TBL] [Abstract][Full Text] [Related]
14. Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. Ghanem S; Valecha GK; Hossri S; Ibrahim U; Atallah JP Expert Opin Investig Drugs; 2017 Dec; 26(12):1317-1319. PubMed ID: 29046065 [No Abstract] [Full Text] [Related]
15. Nivolumab for advanced squamous cell lung cancer: what are the next steps? de Mello RA; Pousa I; Pereira D Lancet Oncol; 2015 Mar; 16(3):234-5. PubMed ID: 25704436 [No Abstract] [Full Text] [Related]
16. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Garon EB Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470 [TBL] [Abstract][Full Text] [Related]
17. Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction. Socinski MA Semin Oncol; 2015 Oct; 42 Suppl 2():S1-2. PubMed ID: 26477469 [No Abstract] [Full Text] [Related]